Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Zidovudine use during pregnancy among HIV-infected women on Medicaid.

Sambamoorthi U, Akincigil A, McSpiritt E, Crystal S.

J Acquir Immune Defic Syndr. 2002 Aug 1;30(4):429-39.

PMID:
12138350
2.

HIV infection and zidovudine use in childbearing women.

Sia J, Paul S, Martin RM, Cross H.

Pediatrics. 2004 Dec;114(6):e707-12. Epub 2004 Nov 15.

PMID:
15545619
3.

Factors associated with zidovudine receipt and prenatal care among HIV-infected pregnant women in New Jersey.

Abatemarco DJ, Catov JM, Cross H, Delnevo C, Hausman A.

J Health Care Poor Underserved. 2008 Aug;19(3):814-28. doi: 10.1353/hpu.0.0039.

PMID:
18677072
4.

Maternal characteristics associated with antenatal, intrapartum, and neonatal zidovudine use in four US cities, 1994-1998.

Orloff SL, Bulterys M, Vink P, Nesheim S, Abrams EJ, Schoenbaum E, Palumbo P, Steketee RW, Simonds RJ; Perinatal AIDS Collaborative Transmission Study.

J Acquir Immune Defic Syndr. 2001 Sep 1;28(1):65-72.

PMID:
11579279
5.

Effectiveness of intensive nurse case management in decreasing vertical transmission of human immunodeficiency virus infection in Wisconsin.

Havens PL, Cuene BE, Hand JR, Gern JE, Sullivan BW, Chusid MJ.

Pediatr Infect Dis J. 1997 Sep;16(9):871-5.

PMID:
9306482
6.

Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women.

Melvin AJ, Burchett SK, Watts DH, Hitti J, Hughes JP, McLellan CL, King PD, Johnson EJ, Williams BL, Frenkel LM, Coombs RW.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1;14(3):232-6.

PMID:
9117455
7.

The impact of zidovudine use in HIV-infected pregnant women on vertical transmission of HIV in Mississippi.

Palmer AL, Gay H, Currier MM.

J Miss State Med Assoc. 2000 Feb;41(2):479-83.

PMID:
10710894
8.

Prenatal and postpartum zidovudine adherence among pregnant women with HIV: results of a MEMS substudy from the Perinatal Guidelines Evaluation Project.

Ickovics JR, Wilson TE, Royce RA, Minkoff HL, Fernandez MI, Fox-Tierney R, Koenig LJ; Perinatal Guidelines Evaluation Group.

J Acquir Immune Defic Syndr. 2002 Jul 1;30(3):311-5.

PMID:
12131568
9.

Effect of prenatal zidovudine on disease progression in perinatally HIV-1-infected infants.

de Souza RS, Gómez-Marín O, Scott GB, Guasti S, O'Sullivan MJ, Oliveira RH, Mitchell CD.

J Acquir Immune Defic Syndr. 2000 Jun 1;24(2):154-61.

PMID:
10935691
10.

Translating clinical trial results into practice: the effect of an AIDS clinical trial on prescribed antiretroviral therapy for HIV-infected pregnant women.

Turner BJ, Newschaffer CJ, Zhang D, Fanning T, Hauck WW.

Ann Intern Med. 1999 Jun 15;130(12):979-86.

PMID:
10383368
11.

Higher placental anti-inflammatory IL-10 cytokine expression in HIV-1 infected women receiving longer zidovudine prophylaxis associated with nevirapine.

Pornprasert S, Mary JY, Faye A, Leechanachai P, Limtrakul A, Rugpao S, Sirivatanapa P, Gomuthbutra V, Matanasaravoot W, Le Coeur S, Lallemant M, Barré-Sinoussi F, Menu E, Ngo-Giang-Huong N; ANRS 1267 study team and HIV-1 PMTCT-PlaNet.

Curr HIV Res. 2009 Mar;7(2):211-7.

PMID:
19275589
12.

Effectiveness of short-term and long-term zidovudine prophylaxis on detection of HIV-1 subtype E in human placenta and vertical transmission.

Bhoopat L, Khunamornpong S, Lerdsrimongkol P, Sirivatanapa P, Sethavanich S, Limtrakul A, Gomutbuthra V, Kajanavanich S, Thorner PS, Bhoopat T.

J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):545-50.

PMID:
16284530
13.

Prevention of mother-to-child transmission of HIV in Thailand: physicians' attitudes on zidovudine use, pregnancy termination, and willingness to provide care.

Stringer JS, Stringer EM, Phanuphak P, Jetwana P, Reinprayoon D, Funkhouser EM, Vermund SH.

J Acquir Immune Defic Syndr. 1999 Jul 1;21(3):217-22.

PMID:
10421245
14.

Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero.

Olivero OA, Shearer GM, Chougnet CA, Kovacs AA, Landay AL, Baker R, Stek AM, Khoury MM, Proia LA, Kessler HA, Sha BE, Tarone RE, Poirier MC.

AIDS. 1999 May 28;13(8):919-25.

PMID:
10371172
15.

Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team.

Lambert JS, Watts DH, Mofenson L, Stiehm ER, Harris DR, Bethel J, Whitehouse J, Jimenez E, Gandia J, Scott G, O'Sullivan MJ, Kovacs A, Stek A, Shearer WT, Hammill H, van Dyke R, Maupin R, Silio M, Fowler MG.

AIDS. 2000 Jul 7;14(10):1389-99.

PMID:
10930154
16.

Success in implementing Public Health Service guidelines to reduce perinatal transmission of HIV--Louisiana, Michigan, New Jersey, and South Carolina, 1993, 1995, and 1996.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 1998 Aug 28;47(33):688-91. Erratum in: MMWR Morb Mortal Wkly Rep 1998 Sep 4;47(34):718.

17.

New mutations associated with resistance not detected following zidovudine monotherapy in pregnancy when used in accordance with British HIV Association guidelines.

Read P, Costelloe S, Mullen J, O'Shea S, Lyons F, Hay P, Welch J, Larbalestier N, Taylor G, de Ruiter A.

HIV Med. 2008 Aug;9(7):448-51. doi: 10.1111/j.1468-1293.2008.00594.x.

18.

Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.

Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, Leroy V, Blanche S, Dabis F, Abrams EJ.

AIDS. 2008 Sep 12;22(14):1815-20. doi: 10.1097/QAD.0b013e32830b8ab9.

PMID:
18753864
19.

From the Centers for Disease Control and Prevention. Progress toward elimination of perinatal HIV infection--Michigan, 1993-2000.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2002 Feb 8;51(5):93-7.

20.

Supplemental Content

Support Center